Lila Sciences

lila.ai →

-43%

est. 2Y upside i

AI & MLHealthcareSeries A

Lila Sciences is the world’s first scientific superintelligence platform and autonomous lab for life, chemistry, and materials science.  We are pioneering a new age of boundless discovery by building the capabilities to apply AI to every aspect of the scientific method.

Rank

#2035

Sector

Artificial Intelligence, Life Sciences, Deep Tech

Est. Liquidity

~5Y

Data Quality

Data: Medium

Lila Sciences operates in an exciting, high-growth market with a strong technological vision and a $1.3B valuation on ~$75M revenue.

Last updated: March 10, 2026

Bull (20%)+300%

Lila Sciences' 'AI Science Factories' achieve breakthrough discoveries, leading to multiple high-value commercial partnerships and a successful lab-as-a-service model. Revenue scales rapidly to $500M+ by 2028, justifying a $5.2B valuation (4x current), driven by strong demand for autonomous scientific discovery and a defensible data moat.

Base (40%)+50%

Lila Sciences secures a limited number of key customers, demonstrating the platform's capabilities in specific niches. However, scaling proves challenging amidst intense competition and high operational costs. Revenue grows to $200M by 2028, leading to a $1.95B valuation (1.5x current), offering a modest return for common shareholders.

Bear (40%)-80%

Established AI giants or well-funded biotech competitors leverage their resources to offer more comprehensive or cost-effective autonomous lab solutions, marginalizing Lila's offerings. The high capital intensity and unproven commercial scalability lead to a down round or acquisition at $260M, wiping out most common stock value due to the $550M liquidation preference.

Est. time to liquidity~5.0 years

Preference Stack Risk

severe

Funding Intensity

42%

Investors hold $550M in liquidation preferences ahead of common stock. In an exit at or below $1.3B, employees with common stock may receive little to nothing until investors recoup their $550M.

Dilution Risk

high

Given the high capital intensity and current profitability status, Lila Sciences will likely require additional significant funding rounds, which will dilute existing equity holders.

Secondary Liquidity

none

There is no public information indicating active secondary markets or tender offers for Lila Sciences' equity.

View all 86 open roles at Lila Sciences →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Lila Sciences's data — designed to show you've done your homework.

  • 1

    “Given the high incumbent threat from large AI labs like OpenAI and established players like Recursion Pharmaceuticals, how does Lila Sciences plan to differentiate its 'AI Science Factories' and secure market share beyond its initial customer cohort?”

  • 2

    “With a $1.3B valuation on ~$75M revenue and high capital intensity, what are the key milestones and financial targets Lila Sciences aims to achieve in the next 24 months to justify its valuation and move towards profitability?”

  • 3

    “Considering the $550M in total funding and the current $1.3B valuation, how is Lila Sciences thinking about a liquidity event timeline for employees, and what are the company's plans regarding future dilution or potential secondary liquidity options?”

Community

Valuation Sentiment

Our model estimates -43% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.